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RA affects naive and already differentiated
T cells is important and may lead to the
identification of possible targets for thera-
peutic interventions to treat various inflam-
matory and autoimmune diseases.
SUPPLEMENTAL DATA
Supplemental Data include one figure and can be
foundwith thisarticleonlineathttp://www.immunity.
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in our recent paper, which showed that
retinoic acid (RA), binding to the RARa
receptor, influences TGFb-induced Foxp3
expression through an indirect manner,
either by repressing IL-6Ra or by damp-
ening theproductionof inhibitory cytokines
(IFN-g, IL-4, and IL-21). Thesourceof these
cytokines, in our culture conditions, was
CD44hi memory and/or effector phenotype
CD4+ T cells. Several other papers have
appeared on the topic, investigating the
responsiveness of isolated naive cells to
RA, a question of importance in under-
standing the molecular mechanisms that
link RA to FoxP3 expression. This letter
offers us the possibility to clarify the issue.
RA could influence FoxP3 induction
through several, nonmutually exclusive,
mechanisms. First, an immediate and
‘‘direct’’ effect leading to activation of
the FoxP3 locus, acting in naive T cells
independently of any other influence
(e.g., by direct transactivation of the
Foxp3 locus or by potentiation of TGF-b
signaling). Second, RA can inhibit the
expression of the IL-6 receptor, thus472 Immunity 30, April 17, 2009 ª2009 Elsedampening the sensitivity to the inhibitory
effect of this cytokine; this mechanism
has been demonstrated by Xiao et al.
and ourselves (Xiao et al., 2008; Hill
et al., 2008). Third, RA can shut down
the synthesis of cytokines (IFN-g, IL-4,
and IL-21), which in concert have an inhib-
itory effect on FoxP3 induction. This is the
mechanism shown in our previous paper
(Hill et al., 2008), by microarray analysis
demonstrating a wholesale shutdown of
cytokine genes by RA, consistent with
other reports (Elias et al., 2008; Takaki
et al., 2008; Maynard et al., 2009).
At issue, then, is whether RA can affect
FoxP3 expression in isolated naive T cells,
independent of other cytokines or other
cellular influences. Experimental condi-
tions in which naive T cells are stimulated
in the presence of IL-6, of dendritic cells,
or of other antigen-presenting cells do not
address the point because they may read
out mechanism #2 (e.g., experiments in
Maynard et al. [2009] and Mucida et al.
[2007]). Some reports have shown direct
responses of carefully isolated naive
T cells (Xiao et al., 2008; Elias et al., 2008;vier Inc.and Figure S1 from the letter of Mucida
et al., 2009). Yet, these inductions are
carried out in conditions of T cell activation
that can readily lead to effector cell dif-
ferentiation, and thus to IFN-g, IL-4, and
IL-21 production (over 4 days’ culture).
Indeed, cytokine-mediated inhibition of
FoxP3 expression may well be at play in
some of these ‘‘naive responder’’ experi-
ments. The progressive inhibition of FoxP3
induction with increasing doses of anti-
CD28, and its reversal by RA (Figure S1
in Mucida et al., 2009), can plausibly be
interpreted as cytokine production that
increases with costimulatory signals. In
the report of Xiao et al. (Xiao et al., 2008),
RA treatment leads to increased Smad3
phosphorylation, and a known effect of
IFN-g signaling is the inhibition of Smad3
phosphorylation (Ulloa et al., 1999).
Thus, although the direct effects of
mechanism #1 remain a possibility (and
one suggested by the existence of an
RAR-responsive element in the body of
Foxp3 [Takaki et al., 2008]), the interplay
between RA and inhibitory cytokines
mean that any claim that FoxP3 induction
Immunity
Lettersin naive T cells is directly influenced by
RA must guard against the possibility
of indirect effects, intercrine or autocrine.
Ultimately, the in vivo situation is that
which matters, and several mechanisms
may contribute to the enhancement of
FoxP3 expression by RA, in the multicel-
lular me´nage that constitutes a lymphoid
organ or tissue. But a clear understanding
of underlying molecular routes will require
reductionist in vitro systems, in which the
inputs and secondary effects are carefully
monitored and controlled.REFERENCES
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